Inhibition of dipeptidyl peptidase-4 (DPP-4): A target to treat type 2 diabetes

Current Enzyme Inhibition

Volumn 7, Issue 4, 2011, Pages 205-217

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Diabetes; DPP 4; GLP 1; Glucagon secretion; Glycemic control; Incretin; Insulin secretion; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; CATALYSIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84858765845     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/157340811799860515     Document Type: Article

References (150)

1. Hopsu-Havu, V.K.; Glenner, G.G. A new dipeptide napthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie, 1966,7, 197-201.
2. Mentlein, R. Dipeptidyl-paptidase IV (CD26)- role in the inactivation of regulatory peptides. Regul. Pept., 1999, 85, 9-24.
3. Kettmann, U.; Humbel, B.; Holzhausen, H.J. Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem., 1992, 92, 225-227.
4. Mentlein, R.; Heymann, E.; Scholz, W.; Feller, A.C.; Flad, H.D. Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. Cell Immunol., 1984, 89, 11-19.
5. Fujiwara, H.; Maeda, M.; Imai, K.; Fukuoka, M.; Yasuda, K.; Takakura, K.; Mori, T. Human luteal cells express dipeptidyl peptidase IV on the cell surface. J. Clin. Endocrinol. Metab., 1992, 75, 1352-1357.
6. Atherton, A.J.; Monaghan, P.; Warburton, M.J.; Robertson, D.; Kenny, A.J.; Gusterson, B.A. Dipeptidyl peptidase IV expressionidentifies a functional sub-population of breast fibroblasts. Int. J. Cancer, 1992, 50, 15-19.
7. Bathon, J.M.; Proud, D.; Mizutani, S.; Ward, P.E. Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides. J. Clin. Invest., 1992, 90, 981-991.
8. Raynaud, F.; Bauvois, B.; Gerbaud, O.; Evain-Brion, D. Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J. Cell Physiol., 1992, 151, 378-385.
9. Mitro, A.; Lojda, Z. Histochemistry of proteases in ependymal, choroid plexus and leptomeninges. Histochemistry, 1988, 88, 645-646.
10. Bernstein, H.G.; Schön, E.; Ansorge, S.; Röse, I.; Dorn, A. Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain. Int. J. Devel. Neurosci., 1987, 5, 237-242.
11. Haninec, P.; Grim, M. Localization of dipeptidylpeptidase IV and alkaline phosphatase in developing spinal cord meninges and peripheral nerve coverings of the rat. Int. J. Devel. Neurosci., 1990, 8, 175-180.
12. Yu, D.M.; Yao, T.W.; Chowdhury S.; Nadvi, N.A.; Osborne, B.; Church WB,; McCaughan G.W.; Gorrell, M.D. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J., 2010, 277, 1126-1144.
13. Lojda, Z. Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels. Histochemistry, 1979, 59, 153-166.
14. Lambeir, A.M.; Durinx, C.; Scharpé, S.; De Meester, I. Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP-IV. Crit. Rev.Clin. Lab. Sci., 2003, 40, 209-294.
15. Hansen, L.; Deacon, C.F.; Ørskov, C.; Holst, J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1- (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology, 1999, 140, 5356-5363.
16. Misumi, Y.; Hayashi, Y.; Arakawa, F.; Ikehara, Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase of the cell surface. Biochim. Biophys. Acta, 1992, 1131, 333-336.
17. Abbott, C.A.; Baker, E.; Sutherland, G.R.; McCaughan, G.W. Genomic organization, exact localization, and tissue expression ofthe human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics, 1994, 40, 331-338.
18. Böhm, S.K.; Gum, J.R.; Erickson, R.H.; Hicks, J.W.; Kim, Y.S. Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter. Biochem. J., 1995, 311, 835-843.
19. Hong, W.; Doyle, D. Molecular dissection of the NH2-terminal signal/anchor sequence of rat dipeptidyl peptidase IV. J. Cell Biol., 1990, 111, 323-338.
20. Ludwig, K.; Yan, S.; Fan, H.; Reutter, W.; Böttcher, C. The 3D structure of rat DPPIV/CD26 as obtained by cryo-TEM and single particle analysis. Biochem. Biophys. Res. Commun., 2003, 304, 73-77.
21. Ogata, S.; Misumi, Y.; Tsuji, E.; Takami, N.; Oda, K.; Ikehara, Y. Identification of the active site residues in dipeptidyl peptidase IV by affinity labellng and site-directed mutagenesis. Biochemistry, 1992, 31, 2582-2587.
22. Nausch, I.; Mentlein, R.; Heymann, E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol. Chem. Hoppe-Seyler, 1990, 371, 1113-1118.
23. Bongers, J.; Lambros, T.; Ahmad, M.; Heimer, E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta, 1992, 1122, 147-153.
24. Deacon, C.F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 2004, 36, 761-765.
25. Mentlein, R.; Gallwitz, B.; Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide- 1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 1993, 214, 829-835.
26. Drucker, D.J.; Shi, Q.; Crivici, A.; Sumner-Smith, M.; Tavares, W.; Hill, M.; DeForest, L.; Cooper, S.; Brubaker, P.L. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotechnol., 1997, 15, 673-677.
27. Löster, K.; Zeilinger, K.; Schuppan, D.; Reutter, W. The cysterinerich region of dipeptidyl peptidase IV (CD 26) is the collagenbinding site. Biochem. Biophys. Res. Commun., 1995, 217, 341-348.
28. Damholt, A.B.; Buchan, A.M.; Holst, J.J.; Kofod, H. Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Endocrinology, 1999, 140, 4800-4808.
29. Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet, 1987, 2, 1300-1304.
30. Nauck, M.A.; Niedereichholz, U: Ettler, R; Holst, J.J.; Ørskov, C.; Ritzel, R.; Schmiegel, W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effets in healthy humans. Am. J. Physiol., 1997, 273, E981-E988.
31. Dunning, B.E.; Foley, J.E.; Ahrén, B. Alpha cell function in healthy and disease: influence of glucagon-like peptide-1. Diabetologia, 2005, 48, 1700-1713.
32. Deacon, C.F.; Ahrén, B. Physiology of incretins in health and disease. Rev. Diabet. Stud., 2011, 8, 293-306.
33. Ahrén, B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. BioEssays, 1998, 20, 642-651.
34. Drucker, D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol., 2003, 17, 161-171.
35. Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
36. Gutniak, M.; Ørskov, C.; Holst, J.J.; Ahrén, B.; Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide innormal subjects and in patients with diabetes mellitus. N. Engl. J. Med., 1992, 326, 1316-1322.
37. Nauck, M.A.; Kleine, N; Ørskov, C.; Holst, J.J.; Willms, B.; Creutzfeldt, W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36)amide in type 2 (noninsulin- dependent) diabetic patients. Diabetologia, 1993, 36, 741-744.
38. Gutniak, M.K.; Larsson, H.; Heiber, S.J.; Juneskans, O.T.; Holst, J.J.; Ahrén, B. Potential therapeutic levels of glucagon-like peptide- 1 achieved in humans by a buccal tablet. Diabetes Care, 1996, 19,843-848.
39. Gutniak, M.K.; Larsson, H.; Sanders, S.W.; Juneskans, O.; Holst, J.J.; Ahrén, B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care, 1997, 20, 1874-1879.
40. Zander, M.; Madsbad, S.; Lysgaard Madsen, J.; Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 2002, 359, 824-830.
41. Egan, J.M.; Bulotta, A.; Hui, H.; Perfetti, R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab. Res. Rev., 2003, 19, 115-123.
42. Ahrén, B. Gut peptides and type 2 diabetes mellitus treatment. Curr. Diab. Rep., 2003, 3, 365-372.
43. Ahrén, B. GLP-1 for type 2 diabetes. Exp. Cell Res., 2011, 317, 1239-1245.
44. Meier, J.J.; Nauck, M.A.; Schmidt, W.E.; Gallwitz, B. Gastric inhibitory polypeptide: the negleted incretin revisited. Regul. Pept., 2002, 107, 1-13.
45. Nauck, M.; Stockmann, F.; Ebert, R.; Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 1986, 29, 46-52.
46. Buckley, D.I.; Lundquist, P. Analysis of the degradation of insulinotropic [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs. Regul. Pept., 1992, 40, 117.
47. Deacon, C.F.; Nauck, M.A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2 terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44, 1126-1131.
48. Kieffer, T.J.; McIntosh, C.H.; Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136, 3585-3596.
49. Deacon, C.F.; Johnsen, A.H.; Holst, J.J. Degradation of glucagonlike peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab., 1995, 80, 952-957.
50. Knudsen, L.B.; Pridal, L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol., 1996, 318, 429-435.
51. Rolin, B.; Deacon, C.F.; Carr, R.D.; Ahrén, B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or iinsulin levels in mice. Eur. J. Pharmacol., 2004, 494, 283-288.
52. Vilsbøll, T.; Agersø, H.; Krarup, T.; Holst, J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab., 2003, 88, 220-224.
53. Meier, J.J.; Nauck, M.A.; Kranz, D.; Holst, J.J.; Deacon, C.F.; Gaeckler, D.; Schmidt, W.E.; Gallwitz, B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes, 2004, 53, 654-662.
54. Deacon, C.F.; Nauck, M.A.; Meier, J.; Hucking, K.; Holst, J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab., 2000, 85, 3575-3581.
55. Holst, J.J.; Deacon, C.F. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type diabetes. Diabetes, 1998, 47, 1663-1670.
56. Nauck, M.A.; Heimesaat, M.M.; Ørskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest., 1993, 91, 301-307.
57. Højberg, P.V.; Vilsbøll, T.; Rabøl, R.; Knop, F.K.; Bache, M.; Krarup, T.; Holst, J.J.; Madsbad, S. Four weeks of nearnormalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia, 2009, 52, 199-207.
58. Fujiwara, T.; Tsuji, E.; Misumi, Y.; Takami, N.; Ikehara, Y. Selective cell-surface expression of dipeptidyl peptidase IV withmutations at the active site sequence. Biochem. Biophys. Res. Commun., 1992, 185, 776-784.
59. Watanabe, Y.; Kojima, T.; Fujimoto, Y. Deficiency of membrane bound dipeptidyl aminopeptidase IV in a certain rat strain. Experentia, 1987, 43, 400-401.
60. Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IVdeficient Fischer rats. Biochem. Biophys. Res. Commun., 2001, 284, 501-506.
61. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.M.; Pierres, M.; Nielsen, P.F.; Ribel, U.; Watanabe, T.; Drucker, D.J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA, 2000, 97, 6874-6879.
62. Püschel, G.; Mentlein, R.; Heymann, E. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur. J. Biochem., 1982, 126, 359-365.
63. Coutts, S.J.; Kelly, T.A.; Snow, R.J.; Kennedy, C.A.; Barton, R.W.; Adams, J.; Krolikowski, D.A.; Freeman, D.M.; Campbell, S.J.; Ksiazek, J.F.; Bachovchin, W. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J. Med. Chem., 1996, 39, 2087-2094.
64. Rahfeld, J.; Schierhorn, M.; Hartrodt, B.; Neubert, K.; Heins, J. Are diprotin A (Ile-Pro-Ile) and diprotin B (val-pro-leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim. Biophys. Acta, 1991, 1076, 314-316.
65. Demuth, H.U.; Heins, J. In: Austin, R.G. Dipeptidyl Peptidase IV (CD 26) in Metabolism and the Immuno Response, 1995, pp. 1-35.
66. Ashworth, D.M.; Atrash, B.; Baker, G.R.; Baxter, A.J.; Jenkins, P.D.; Jones, D.M.; Szelke, M. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Biorg. Med. Chem. Lett., 1996, 6, 1163-1166.
67. Sorbera, L.A.; Revel, L.; Castagner, J. P32/98: antidiabetic dipeptidyl peptidase IV inhibitor. Drugs Future, 2001, 26, 859-864.
68. Pauly, R.P.; Demuth, H.U.; Rosche, F.; Schmidt, J.; White, H.A.; Lynn, F.; McIntosh, C.H.; Pederson, R.A. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide. Metabolism, 1999, 48, 385-389.
69. Pederson, R.A.; White, H.A.; Schlenzig, D.; Pauly, R.P.; McIntosh, C.H.; Demuth, H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes, 1998, 47, 1253-1258.
70. Parmee, E.R.; He, J.; Mastracchio, A.; Edmondson, S.D.; Colwell, L.; Eiermann, G.; Freeney, W.P.; Habulihaz, B.; He, H.; Kilburn, R.; Leiting, B.; Lyons, K.; Marsilio, F.; Patel, R.A.; Petrov, A., DiSalvo, J.; Wu, J.K.; Thornberry, N.A.; Weber, A.E. 4-amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 43-46.
71. Ashton, W.T.; Dong, H.; Sisco, R.M.; Doss, G.A.; Leiting, B.; Patel, R.A.; Wu, J.K.; Marsilio, F.; Thornberry, N.A.; Weber, A.E. Diasteroselective synthesis and configuration-dependent activity of (3-substituted cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 859-863.
72. Caldwell, C.G.; Chen, P.; He, J.; Parmee, E.R.; Leiting, B.; Marsilio, F.; Patel, R.A.; Wu, J.K.; Eiermann, G.J.; Petrov, A.; He, H.; Lyons, K.A.; Thornberry, N.A.; Weber, A.E. & Fluopyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 1265-1268.
73. Hughes, T.E.; Mone, M.D.; Russell, M.E.; Weldon, S.C.; Villhauer, E.B. NVP-DPP728 (1-[[[2-[(5-cyanopyridine-2- yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slowbinding inhibitor of dipeptidyl peptidase IV. Biochemistry, 1999, 38, 11597-11603.
74. Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Burkey, B.F.; Dunning, B.E.; Prasad, K.; Mangold, B.L.; Russell, M.E.; Hughes, T.E. 1-[[(3-hydroxy-1-adamantyl)amino]ethyl]-2-cyano-(S)- pyrrolidine: a potent, selective and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem., 2003, 46, 2774-2789.
75. Magnin, D.R.; Robl, J.A.; Sulsky, R.B.; Augeri, D.J.; Huang, Y.; Simpkins, L.M.; Taunk, P.C.; Betebenner, D.A.; Robertson, J.G.; Abboa-Offei, B.E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D.F.; Malley, M.F.; Gougoutas, J.Z.; Khanna, A.; Huang, Q.; Han, S.P.; Parker, R.A.; Hamann, L.G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-1-cis-4,5- methanoprolinenitrile-based inhibitors. J. Med. Chem., 2004, 47, 2587-2598.
76. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.J.; Fisher, M.H.; He, H.; Hickey, G.J.; Kowalchick, J.E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, S.B.; Roy, R.S.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.B.; Zhu, L.; Thornberry, N.A.; Weber, A.E. (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin- 7-(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48,141-151.
77. Augeri, D.J.; Robl, J.A., Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; Han, S.P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzél, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48, 5025-5037.
78. Feng, J.; Zhang, Z.; Wallace, M.B.; Stafford, J.A.; Kaldor, S.W.; Kassel, D.B.; Navre, M.; Shi, L.; Skene, R.J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D.R.; Gwaltney, S.L. 2nd. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem., 2007, 50, 2297-2300.
79. Eckhardt, M.; Langkopf, E.; Mark, M.; Tadayyon, M.; Thomas, L.; Nar, H.; Pfrengle, W.; Guth, B.; Lotz, R.; Sieger, P.; Fuchs, H.; Himmelsbach, F. 8-(3-®-aminoperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6- dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2007, 50, 6450-6453.
80. Deacon, C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab.,2011, 13, 7-18.
81. Rosenblum, J.S.; Kozarich, J.W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol., 2003, 7, 496-504.
82. Lankas, G.R.; Leiting, B.; Roy, R.S.; Eiermann, G.J.; Beconi, M.G.; Biftu, T.; Chan, C.C.; Edmondson, S.; Feeney, W.P.; He, H.; Ippolito, D.E.; Kim, D.; Lyons, K.A.; Ok, H.O.; Patel, R.A.; Petrov, A.N.; Pryor, K.A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J.K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A.E.; Thornberry, N.A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 2005, 54, 2988-2994.
83. Burkey, B.F.; Hoffmann, P.K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J.E. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes. Metab., 2008, 10,1057-1061.
84. Deacon, C.F.; Hughes, T.E.; Holst, J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes, 1998, 47, 764-769.
85. Ahrén, B.; Holst, J.J.; Mårtensson, H.; Balkan, B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol., 2000, 404, 239-245.
86. Balkan, B.; Kwasnik, L.; Miserendineo, R.; Holst, J.J.; Li, X. Inhibition of dipetidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia, 1999, 42, 1324-1331.
87. Reimer, M.K.; Holst, J.J.; Ahrén, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol., 2002, 146, 717-727.
88. Pospisilik, J.A.; Stafford, S.G.; Demuth, H.U.; Brownsey, R.; Parkhouse, W.; Finegood, D.T.; McIntosh, C.H.; Pederson, R.A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes, 2002, 51, 943-950.
89. Winzell, M.S.; Ahrén B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes, 2004, 53 (Suppl 3), S215-S219.
90. Hui, H.; Perfetti, R. Pancreas duodenum homeobo-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur. J. Endocrinol., 2002, 146, 129-141.
91. Ahrén, B.; Winzell, M.S.; Wierup, N.; Sundler, F.; Burkey, B.; Hughes, T.E. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with betacell- specific overexpression of human islet amyloid polypeptides. Regul. Pept., 2007, 143, 97-103.
92. Mu, J.; Petrov, A.; Eiermann, G.J.; Woods, J.; Zhou, Y.P.; Li, Z.; Zycband, E.; Feng, Y.; Zhu, L.; Roy, R.S.; Howard, A.D.; Li, C.; Thornberry, N.A.; Zhang, B.B. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol., 2009,623,148-154
93. Furuta, Y.; Horiguchi, M.; Sugaru, E.; Ono-Kishino, M.; Otani, M.; Masui, Y.; Tsuchida, A.; Sato, Y.; Takubo, K.; Hochigai, H.; Kimura, H.; Nakahira, H.; Nakagawa, T.; Taiji, M. Chronic administration of DSP-7238, a novel, potent, specific and substrateselective PP IV inhibitor, improves glycaemic control and ß-cell damage in diabetic mice. Diabetes Obes. Metab., 2010, 12, 421-436.
94. Duttaroy, A.; Voelker, F.; Merriam, K.; Zhang, X.; Ren, X.; Subramanian, K.; Hughes, T.E.; Burkey, B.F. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur. J. Pharmacol., 2011, 650, 703-707.
95. Pospisilik, J.A.; Martin, J.; Doty, T.; Ehses, J.A.; Pamir, N.; Lynn, F.C.; Piteau, S.; Demuth, H.U.; McIntosh, C.H.; Pederson, R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 2003, 52, 741-750.
96. Deacon, C.F.; Wamberg, S.; Bie, P.; Hughes, T.E.; Holst, J.J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol., 2002, 172, 355-362.
97. El-Ouaghlidi, A.; Rehring, E.; Holst, J.J.; Schweizer, A.; Foley, J.; Holmes, D.; Nauck, M.A. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J. Endocrinol. Metab., 2007, 92, 4165-4171.
98. Sudre, B.; Broqua, P.; White, R.B.; Ashworth, D.; Evans, D.M.; Haigh, R.; Junien, J.L.; Aubert, M.L. Chronic inhibition ofcirculating dipeptidyl peptidase IV be FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes, 2002, 51, 1461-1469.
99. Ahrén, B.; Hughes, T.E. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology, 2005, 146, 2055-2059.
100. Hansotia, T.; Baggio, L.L.; Delmeire, D.; Hinke, S.A.; Yamada, Y.; Tsukiyama, K.; Seino, Y.; Holst, J.J.; Schuit, F.; Drucker, D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes, 2004, 53, 1326-1335.
101. asseboeuf, M.; Cattan, P.; Armanet, M.; Karaca, M.; Castel J; Garret, C.; Payros, G.; Maida, A.; Sulpice, T.; Holst, J.J.; Drucker, D.J.; Magnan, C.; Burcelin, R. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemic in mice. Endocrinology, 2011, 152, 3018-3029.
102. Ahrén, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.A.; Sandqvist, M.; Båvenholm, P.; Efendic, S.; Eriksson, J.W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 2002, 25, 869-875.
103. Ahrén, B.; Landin-Olsson, M.; Jansson, P.A.; Svensson, M.; Dolmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89, 2078-2084.
104. Ahrén, B.; Foley, J.E.; Bosi, E. Clinical evidence and mechanistic basis for vildagliptińs action when added to metformin. Diabetes Obes. Metab., 2011, 13, 193-203.
105. Ahrén, B.; Foley, J.E. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int. J. Clin. Pract., 2008, 159 (Suppl 1), 8-14.
106. Ahrén, B. DPP-4 inhibition and islet function. J. Diabet. Invest., 2012, in press.
107. Ahrén, B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin. Emerg. Drugs, 2008, 13, 593-607.
108. Dejager, S.; Razac, S.; Foley, J.E.; Schweizer, A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res., 2007, 39, 218-223.
109. Aschner, P.; Kipnes, M.S.; Lunceford, J.K.; Sanchez, M.; Williams-Herman, D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 2006, 29, 2632-2637.
110. Rosenstock, J.; Sankoh, S.; List, J.F. Glucose-lowering activity of the dipepotidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes. Metab., 2008, 10, 376-386.
111. De Fronzo, R.A.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2008, 31, 2315-2317.
112. Del Prato, S.; Barnett, A.H.; Huisman, H.; Neubacher, D.; Woerle, H.J.; Dugi, K.A. Effect of linagliptin monotherapy on glycaemic control and markers of ß-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab., 2011, 13, 258-267.
113. Charbonnel, B.; Karasik, A.; Liu, J.; Wu, M.; Meininger, G. Efficacy and safety of the di peptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 2006, 29, 2638-2643.
114. Ferrannini, E.; Fonseca, V.; Zinman, B.; Matthews, D.; Ahrén, B.; Byiers, S.; Shao, Q.; Dejager, S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab., 2009, 11, 157-166.
115. Jadzinsky, M.; Pfützner, A.; Paz-Pacheco, E.; Xu, Z.; Allen, E.; Chen, R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab., 2009, 11, 611-622.
116. DeFronzo, R.A.; Hissa, M.N.; Garber, A.J.; Luiz Gross, J.; Yuyan Duan, R.; Ravichandran, S.; Chen, R.S. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32, 1649-1655.
117. Nauck M.A.; Ellis, G.C.; Fleck, P.R.; Wilson, C.A.; Mekki, W. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int. J. Clin. Pract., 2009, 63, 46-55.
118. Taskinen, M.R.; Rosenstock, J.; Tamminen, I.; Kubiak, R.; Patel, S.; Dugi, K.A.; Woerle, H.J. Safety and efficacy of linagliptin as add-on therapy to met formin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab., 2011, 13, 65-74.
119. Garber, A.J.; Foley, J.E.; Banerji, M.A.; Ebeling, P.; Gudbjörnsdottir, S.; Camisasca, R.P.; Couturier, A.; Baron, M.A. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabet Obes. Metab., 2008, 10, 1047-1056.
120. Hermansen, K.; Kipnes, M.; Luo, E.; Fanurik, D.; Khatami, H.; Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabet Obes. Metab., 2007, 9, 733-745.
121. Chacra, A.R.; Tan, G.H.; Apanovitch, A.; Ravichandran, S.; List, J.; Chen, R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int. J. Clin. Pract., 2009, 63, 1395-1406.
122. Pratley, R.E.; Kipnes, M.S.; Fleck, P.R.; Wilson, C.; Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes. Med., 2009, 11, 167-176.
123. Owens, D.R.; Swallow, R.; Dugi, K.A.; Woerle, H.J. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24- week randomized study. Diabet. Med., 2011, 28, 1352-1361.
124. Garber, A.J.; Schweizer, A.; Baron, M.A.; Rochoffe, E.; Dejager, S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab., 2007, 9, 166-174.
125. Rosenstock, J.; Brazg, R.G.; Andryuk, P.J.; Lu, K.; Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther., 2006, 28, 1556-1568.
126. Hollander, P.L.; Li, J.; Frederich, R.; Allen, E., Chen, R. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab. Vasc. Dis. Res., 2011, 8, 125-135.
127. Pratley, R.E.; Reusch, J.E.; Fleck, P.R.; Wilson, M.A.; Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr. Med. Res. Opin., 2009, 25, 2361-2371.
128. Gomis, R.; Espadero, R.M.; Jones, R.; Woerle, H.J.; Dugi, K.A. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequastely controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab., 2011, 13, 653-661.
129. Fonseca, V.; Schweizer, A.; Albrecht, D.; Baron, M.A.; Chang, I.; Dejager, S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, 2007, 50, 1148-155.
130. Vilsboll, T.; Rosenstock, J.; Yki-HJärvinen, H.; Cefalu, W.T.; Chen, Y.; Luo, E.; Musser, B.; Andryuk, P.J.; Ling, Y.; Kaufman, K.D.; Amatruda, J.M.; Engel, S.S.; Katz, L. Efficacy and safety of sitalgiptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes. Metab., 2010, 12, 167-177.
131. Rosenstock, J.; Rendell, M.S.; Gross, J.L.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diab etes Obes. Metab., 2009, 11, 1145-1152.
132. Scheen, A.J.; Charpentier, G.; Östgren, C.J.; Hellqvist, A.; Gause- Nilsson, I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev., 2010, 26, 540-549.
133. Chan, J.C.; Scott, R.; Arjona Ferreira, J.C.; Sheng, D.; Gonzalez, E.; Davies, M.J.; Stein, P.P.; Kaufman, K.D.; Amatruda, J.M.; Williams-Herman, D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab., 2008, 10, 545-555.
134. Lukashevich, V.; Schweizer, A.; Shao, Q.; Groop, P.H.; Kothny, W. Safety and efficiency of vildagliptin vs. placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab., 2011, 13, 947-954.
135. Nowicki, M.; Rychlik, I.; Haller, H.; Warren, M.L.; Suchower, L.; Gause-Nilsson, I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes. Metab., 2011, 13, 523-532.
136. Matikainen, N.; Mänttäri, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning BE.; Foley, J.E.; Taskinen, M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49, 2049-2057.
137. Williams-Herman, D.; Engel, S.S.; Round, E.; Johnson, J.; Golm, G.T.; Guo, H.; Musser, B.J.; Davies, M.J.; Kaufman, K.D.; Goldstein, B.J. Safety and tolerability of saxagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr. Disord., 2010, 10, 7.
138. Schweizer, A.; Dejager, S.; Foley, J.E.; Couturier, A.; Ligueros- Saylan, M.; Kothny, W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 disabetes population. Diabetes Obes. Metab. 2010, 12, 485-494.
139. Frederich, R.; Alexander, J.H.; Fiedorek, F.T.; Donovan, M.; Berglind, M.; Harris, S.; Chen, R.; Wolf, R.; Mahaffey, K.W. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Poststgrad. Med., 2010, 122, 16-27.
140. Dore, D.D.; Seeger, J.D.; Arnold Chan, K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin., 2009, 25, 1019-1027.
141. Monami, M.; Dicembrini, I.; Martelli, D.; Mannucci, E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr. Med. Res. Opin., 2011, 27 (Suppl 3), 57-64.
142. Monami, M.; Dicembrini, I.; Antenore, A.; Mannucci, E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a metaanalysis of randomized clinical trials, Diabetes Care, 2011, 34, 2474-2476.
143. Barnett, A.H. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr. Med. Res. Opin., 2010, 26, 1333-1342.
144. Nauck, M.A.; Meininger, G.; Sheng, D.; Terranella, L.; Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab., 2007, 9, 194-205.
145. Filozof, C.; Gautier, J.E. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med., 2010, 27, 318-326.
146. Göke, B.; Gallwitz, B.; Eriksson, J.; Hellqvist, A.; Gause-Nilsson, I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52- week randomized controlled trial. Int. J. Clin. Pract., 2010, 64, 1619-1631.
147. Arechavelata, R.; Seck, T.; Chen, Y.; Krobot, K.J.; ONeill, E.A.; Duran, L.; Kaufman, K.D.; Williams-Herman, D.; Goldstein, B.J. Efficacy and safety with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind non-inferiority trial. Diabetes Obes. Metab., 2011, 13, 160-168.
148. Ahrén, B.; Schweizer, A.; Dejager, S.; Dunning, B.E.; Nilsson, P.M.; Persson, M.; Foley, J.E. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2009, 94, 1236-1243.
149. Foley, J.E.; Jordan, J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc. Health Risk Manag., 2010, 6, 541-548.
150. Ahrén, B. Exenatide: a novel treatment of type 2 diabetes. Therapy, 2005, 2, 207-222.